Proposal for novel histological findings of colorectal liver metastases with preoperative chemotherapy

Kazuyuki Ishida, Noriyuki Uesugi, Yasushi Hasegawa, Ryo Sugimoto, Takeshi Takahara, Koki Otsuka, Hiroyuki Nitta, Tomonori Kawasaki, Go Wakabayashi and Tamotsu Sugai

Departments of Molecular Diagnostic Pathology and Surgery, Iwate Medical University, Morioka, Japan

This study aimed to clarify the histological characteristics related to preoperative chemotherapy for colorectal liver metastases (CRLM). Sixty-three patients with CRLM were divided into two groups: CRLM with chemotherapy (41 cases, group A) and CRLM without chemotherapy (22 cases; surgical treatment alone, group S) to identify the histological differences associated with chemotherapy. In addition, we investigated the effects of combination chemotherapy on the histology of metastatic lesions. Infarct-like necrosis (ILN), three-zonal changes, and cholesterol clefts were more frequent in group A than in group S (P < 0.05). ILN and three-zonal changes were more common in the 5-FU with leucovorin and oxaliplatin (FOLFOX), or 5-FU with leucovorin and irinotecan (FOLFIRI) with or without additional bevacizumab groups than in group S (P < 0.05). Cholesterol clefts in the FOLFOX or FOLFIRI with bevacizumab group and foamy macrophages in the FOLFOX or FOLFIRI group were more common than in group S (P < 0.05). Cases with more than three of the four histological findings—i.e., ILN, three-zonal changes, cholesterol clefts, and foamy macrophages—were more frequent in the FOLFOX or FOLFIRI with or without additional bevacizumab groups than in group S (P < 0.05). We showed histological findings for every representative chemotherapy regimen for CRLM to clarify the effects of preoperative chemotherapy.

Key words: chemotherapy regimen, cholesterol clefts, colorectal liver metastases, foamy macrophages, histological findings, infarct-like necrosis, preoperative chemotherapy, three-zonal changes

Colorectal carcinoma is one of the most common cancers in the world. It has an estimated incidence of 43.7 per 100 000 with over 136 000 estimated new cases expected in the United States in 2014, as reported by the Centers for Disease Control. Liver metastasis is the most common complication of colorectal cancer, and approximately 50% of patients develop colorectal liver metastases (CRLM) at some point during the course of their disease. Patients who are candidates for surgical resection of their liver metastases can expect a prolonged survival or even a cure. However, the resectability rate of metastases at the time of diagnosis is low, accounting for the low proportion of patients who may benefit from a surgical approach. Preoperative chemotherapy provides the potential for unresectable tumors to become resectable if they become smaller in response to treatment. The efficacy of preoperative chemotherapy is generally assessed by radiological evaluation. The radiological response according to the Response Evaluation Criteria in Solid Tumors (RECIST) corresponds to the reduction in the number and size of metastases, essentially a tumor shrinkage. However, preoperative radiology has been shown to overestimate the downstaging of the tumor, and histology remains the best way of assessing residual tumor viability.

Previously, the standard treatment for advanced colorectal cancer was 5-fluorouracil (5-FU)-based chemotherapy with or without leucovorin. Recently, new therapeutic approaches have predominated. Oxaliplatin (trans-1-diaminocyclohexane oxalatoplatinum) or irinotecan-based neoadjuvant chemotherapy alters the natural history of unresectable CRLM by downstaging the disease, allowing resection and prolonging survival in some patients. Additionally, bevacizumab (Avastin), a monoclonal humanized antibody directed against
vascular endothelial growth factor (VEGF), has been shown to extend overall survival in patients treated with 5-FU-based chemotherapy.16–19

Recent studies have shown that the pathological tumor response to chemotherapy is an important factor in patients treated with preoperative chemotherapy for CRLM. Moreover, grading of the histologic response of tumors to preoperative chemotherapy correlates with postoperative disease-free and overall survival.17,20,21 Despite the increasing importance of and opportunity for histological evaluation of preoperative chemotherapy, detailed histological findings for evaluating its effectiveness, and differences associated with various treatment regimens have not yet been proposed. The aim of this study was to identify and standardize the histological findings related to preoperative chemotherapy for CRLM.

MATERIALS AND METHODS

Ethical approval

The study was approved by the institutional review board of Iwate Medical University.

Patient population

All patients (n = 63) with colorectal carcinoma who underwent a first hepatic resection for liver metastases at the Iwate Medical University Hospital from 2008 to 2012 were examined. There were 41 men and 22 women, with ages ranging from 41 to 87 years (mean, 66 years). Eleven patients had a synchronous liver metastasis with colon cancer, and 52 patients had metachronous metastases. In patients undergoing multiple resections for metastatic lesions, only the first resection was included in this study. We included all cases, irrespective of whether they had received preoperative chemotherapy. Surgical resection was the only treatment in 22 cases. Systemic chemotherapy was administered before hepatic surgery in 41 cases. Among the chemotherapeutic agents used were 5-FU, 5-FU with leucovorin and oxaliplatin (FOLFOX), 5-FU with leucovorin and irinotecan (FOLFIRI), and FOLFOX or FOLFIRI with bevacizumab (BV). Several different protocols were used: 11 patients received 5-FU only (5-FU group); 9 patients received FOLFOX or FOLFIRI (FOLFOX or FOLFIRI group); and 21 patients received FOLFOX or FOLFIRI with BV (FOLFOX or FOLFIRI with BV group).

Tissues and pathological assessment

All archival slides of CRLM, which were originally prepared from formalin-fixed, paraffin-embedded tissue, were reviewed. Histological examination of the hepatectomy specimens was made according to our routine hospital process. In patients with multiple metastases, sections of the lesion with the maximum diameter were examined and samples were systematically taken for histology from the whole selected section. Histopathological examination was performed using hematoxylin and eosin staining. Slides were independently examined by two experienced pathologists (K.I and N.U.), who were unaware of the subject's clinical data; specifically, no information was available on the administration and the regimen of preoperative chemotherapy. In some cases for which the evaluation provided different results, a consensus interpretation was reached after re-examination.

The following histological features were evaluated: usual necrosis (UN), infarct-like necrosis (ILN), three-zonal changes, dangerous halos, cholesterol clefts, foamy macrophages and calcification. Usual necrosis was defined as containing nuclear debris in a patchy distribution, with the necrosis admixed and bordered by viable cells. In contrast, ILN was defined as being composed of large confluent areas of eosinophilic cytoplasmic remnants located centrally within a lesion with absent or minimal admixed nuclear debris.22 Three-zonal changes were recognized as a central zone of necrosis, a mid zone of fibrosis and an outer zone of residual tumor.23 Dangerous halos showed that viable tumor cells appeared to infiltrate the surrounding liver parenchyma without a fibroinflammatory reaction (Fig. 1).24 Both UN and ILN were defined as positive when they occupied more than 5% of the tumor area. Cholesterol clefts, foamy macrophages and calcification were regarded as clearly existing cases with positive judging from low to middle power magnification (Fig. 2).

The presence of residual tumor cells was scored for each CRLM according to the modified tumor regression grade (mTRG), which is similar to the tumor regression grade (TRG), with the exception that ILN was considered equivalent to fibrosis.21,22 TRG1 corresponded to the absence of tumor cells replaced by abundant fibrosis; TRG2 corresponded to rare residual tumor cells scattered throughout abundant fibrosis; TRG3 corresponded to more residual tumor cells throughout the predominant fibrosis; TRG4 corresponded to a large amount of tumor cells predominating over fibrosis; and TRG5 corresponded to the almost exclusive presence of tumor cells without fibrosis. The mTRG score was categorized into three groups using previously published guidelines.21 mTRG1 and mTRG2 were categorized as having complete or major histological tumor response (MJHR); mTRG3 was categorized as having partial histological tumor response (PHR); and mTRG4 and mTRG5 were categorized as having no histological tumor regression or response (NHR).

Statistical analysis

The χ²-test was used to correlate the different groups of patients according to the use of preoperative treatment and
the type of chemotherapy versus the presence of histological findings. A result was considered statistically significant if \( P < 0.05 \).

**RESULTS**

**Histological changes in samples of CRLM with chemotherapy versus samples of CRLM without chemotherapy**

Sixty-three patients with CRLM were divided into two groups: CRLM with preoperative chemotherapy (41 cases) and CRLM without preoperative chemotherapy (22 cases, surgery-alone group) in order to identify histological differences associated with chemotherapy. Clinicopathological characteristics of patients treated with surgery alone or with preoperative chemotherapy for CRLM are summarized in Table 1. There was a significant difference in the number of liver metastases between the surgery-alone group and the FOLFOX or FOLFIRI with BV group \( (P < 0.01) \).

Histological findings of the surgery-alone group and preoperative chemotherapy groups are summarized in Table 2. There were low frequencies of ILN, three-zonal changes, and cholesterol clefts in the surgery-alone group (1/22 [4.5%], 4/22 [18.2%], and 5/22 [22.7%], respectively), while the frequencies of these findings in the chemotherapy group (18/22 [43.9%], 20/22 [48.8%], and 20/22 [48.8%], respectively)
were significantly higher \((P < 0.05)\). However, there were no differences in the frequency of UN, dangerous halos, foamy macrophages or calcification between the two groups.

**Histological changes in CRLM following combination chemotherapy**

Histological findings by type of preoperative chemotherapy for CRLM are shown in Table 3. The frequencies of ILN and three-zonal changes between the FOLFOX or FOLFIRI group \((4/9 [44.4\%], 5/9 [55.6\%], \text{respectively})\) and the FOLFOX or FOLFIRI with BV group \((12/21 [57.1\%], 11/21 [52.4\%], \text{respectively})\) were significantly higher than those of the surgery-alone group \((1/22 [4.5\%], 4/22 [18.2\%], \text{respectively})\) \((P < 0.05)\). Foamy macrophages were more common in the FOLFOX or FOLFIRI with BV group \((8/9 [88.9\%])\) than in the surgery-alone group \((5/22 [22.7\%])\) \((P < 0.01)\). Foamy macrophages were more common in the FOLFOX or FOLFIRI with BV group \((8/9 [88.9\%])\) than in the surgery-alone group \((11/22 [50\%])\) \((P < 0.05)\). In contrast, the frequency of UN in the FOLFOX or FOLFIRI with BV group \((16/21 [76.2\%])\) was significantly lower than in the surgery-alone group \((22/22 [100\%])\) \((P < 0.05)\). No significant differences in dangerous halos and calcification were found between the surgery-alone group and the three preoperative chemotherapy groups.

**Histological assessment of the effects of combination chemotherapy in CRLM**

Correlations between the numbers of histological findings and the type of preoperative chemotherapy for CRLM are

---

### Table 1

| Parameter                           | Surgery alone | 5-FU | FOLFOX or FOLFIRI | FOLFOX or FOLFIRI with BV |
|-------------------------------------|--------------|------|-------------------|-------------------------|
| Number of cases                     | 22           | 11   | 9                 | 21                      |
| Median age (range), years           | 67.5 (53–87) | 70.0 (48–82) | 61.0 (58–78) | 64.0 (41–77) |
| Male : female ratio                 | 15 : 7       | 4 : 7 | 8 : 1             | 14 : 7                  |
| Synchronous : Metachronous metastases | 6 : 16   | 0 : 11 | 0 : 9             | 5 : 16                   |
| Median number of metastases (range) | 1 (1–4)      | 1 (1–2) | 2 (1–5)          | 4 (1–11)*               |
| Median diameter of largest metastasis (range), mm | 26.5 (14–160) | 24.0 (20–65) | 23.0 (9–67) | 23.0 (7–155) |

*Significantly different from the surgery-alone group \((P < 0.05)\).

5-FU, 5-fluorouracil; BV, bevacizumab; FOLFIRI, 5-fluorouracil with leucovorin and irinotecan; FOLFOX, 5-fluorouracil with leucovorin and oxaliplatin.

### Table 2

| Histological finding | Surgery alone \((n = 22)\) | Preoperative chemotherapy \((n = 41)\) | \(P\) value |
|----------------------|-----------------------------|-------------------------------------|------------|
| Usual necrosis       | 22 (100%)                   | 36 (87.8%)                         | \(P > 0.05\) |
| Infarct-like necrosis| 1 (4.5%)                    | 18 (43.9%)*                        | \(P = 0.0012\) |
| Three-zonal changes  | 4 (18.2%)                   | 20 (48.6%)*                        | \(P = 0.017\) |
| Dangerous halos      | 13 (59.1%)                  | 30 (73.1%)                         | \(P > 0.05\) |
| Cholesterol clefts   | 5 (22.7%)                   | 20 (48.8%)*                        | \(P = 0.044\) |
| Foamy macrophages    | 11 (50.0%)                  | 30 (73.2%)                         | \(P > 0.05\) |
| Calcification        | 8 (36.4%)                   | 17 (41.5%)                         | \(P > 0.05\) |

*Significantly different from the surgery-alone group \((P < 0.05)\).

5-FU, 5-fluorouracil; BV, bevacizumab; FOLFIRI, 5-fluorouracil with leucovorin and irinotecan; FOLFOX, 5-fluorouracil with leucovorin and oxaliplatin.

### Table 3

| Histological finding | Surgery alone \((n = 22)\) | 5-FU \((n = 11)\) | FOLFOX or FOLFIRI \((n = 9)\) | FOLFOX or FOLFIRI with BV \((n = 21)\) | \(P\) value |
|----------------------|-----------------------------|-----------------|-----------------------------|-------------------------------------|------------|
| Usual necrosis       | 22 (100%)                   | 11 (100%)       | 9 (100%)                    | 16 (76.2%)**                        | \(P = 0.015\) |
| Infarct-like necrosis| 1 (4.5%)                    | 2 (18.2%)       | 4 (44.4%)*                  | 12 (57.1%)**                        | \(P = 0.0061\) **\(P = 0.0002\) |
| Three-zonal changes  | 4 (18.2%)                   | 4 (36.4%)       | 5 (55.6%)*                  | 11 (52.4%)*                         | \(P = 0.037\) **\(P = 0.019\) |
| Dangerous halos      | 13 (59.1%)                  | 8 (72.7%)       | 8 (88.9%)                   | 14 (66.7%)                          | \(P > 0.05\) |
| Cholesterol clefts   | 5 (22.7%)                   | 3 (27.3%)       | 4 (44.4%)                   | 13 (61.9%)**                        | \(P = 0.0092\) |
| Foamy macrophages    | 11 (50.0%)                  | 7 (63.6%)       | 8 (88.9%)*                  | 15 (71.4%)                          | \(P = 0.044\) |
| Calcification        | 8 (36.4%)                   | 5 (45.5%)       | 6 (66.7%)                   | 6 (28.6%)                           | \(P > 0.05\) |

***Significantly different from the surgery-alone group \((P < 0.05)\).

5-FU, 5-fluorouracil; BV, bevacizumab; FOLFIRI, 5-fluorouracil with leucovorin and irinotecan; FOLFOX, 5-fluorouracil with leucovorin and oxaliplatin.
summarized in Table 4. We examined how many histological findings (ILN, three-zonal changes, cholesterol clefts, and foamy macrophages) were found in the surgery alone, 5-FU, FOLFOX or FOLFIRI, and FOLFOX or FOLFIRI with BV groups. Cases with all four histological findings were significantly more common in the FOLFOX or FOLFIRI with BV group than in the surgery-alone group (P < 0.001) and the 5-FU group (P < 0.05). The FOLFOX or FOLFIRI group and the FOLFOX or FOLFIRI with BV group were significantly different from the surgery-alone group in satisfying more than three of the four histological findings (P < 0.01). The numbers of cases that had less than or equal to two pathological findings did not differ among the groups.

In the preoperative chemotherapy group, we examined the number of histological findings for CRLM according to tumor regression grade (Table 5). The frequency of MjHR (mTRG1 and mTRG2) and PHR (mTRG3) for cases with more than three histological findings was 57.9% (1/19 [5.3%] and 10/19 [52.6%], respectively). In contrast, MjHR or PHR for cases with less than or equal to two pathological findings was present in only 27.2% of cases (3/22 [13.6%] and 3/22 [13.6%], respectively; P < 0.05).

**DISCUSSION**

The use of surgery for CRLM has expanded with the progress of preoperative chemotherapy, and opportunities are increasing to evaluate the histologic response of tumors to preoperative chemotherapy. Previous histologic grades for preoperative chemotherapy were evaluated by the ratio of fibrosis for tumors that disappeared, and tumors that remained were evaluated on the basis of tumor regression grade (TRG) and Dworak grading. However, it was noted that it was difficult to determine whether the pathological findings resulted from preoperative chemotherapy. This is the first report presenting an objective judgment of histological findings after preoperative chemotherapy.

The ILN, three-zonal changes and cholesterol clefts were among seven histological findings that appeared most often in the preoperative chemotherapy groups in comparison with the surgery-alone group and were regarded as the most important findings that reflected an effect of the preoperative chemotherapy on CRLM. Aloysius et al. reported that the Dworak grading of a group that received FOLFOX4 included in the FOLFOX regimen before hepatectomy for CRLM was significantly higher, and the treatment was histologically effective, compared to that of a control group that underwent hepatectomy only. It was shown that the histological findings of three-zonal changes appeared in FOLFOX4-treated liver nodules, but they were not described with regard to the frequency of appearance and the difference between groups in that report. Fibrosis does not necessarily show where a tumor disappeared, and it might occur with permeation of the tumor. In our study, when we performed a pathological evaluation of CRLM, in addition to determining whether fibrosis is present, it was important that we paid attention to fibrosis between viable tumor cells and necrosis. It was thought that we could evaluate the histological effect of appropriate chemotherapy by judging the three levels of structure to be formed from viable tumor cells, fibrosis and necrosis.
Chemotherapy regimens for CRLM have changed and have progressed from 5-FU alone to FOLFOX and FOLFIRI.\textsuperscript{14,15} Furthermore, it was recently reported that a greater antitumor effect was provided by adding BV, which is an anti-VEGF antibody and panitumumab, which is a human anti-epidermal growth factor receptor (EGFR) monoclonal antibody.\textsuperscript{19,27} However, antitumor effects vary according to the regimen, whereas few reports clarified how histological findings vary. In our results, ILN and three-zonal changes significantly appeared in the FOLFOX or FOLFIRI group and the FOLFOX or FOLFIRI with BV group in comparison with the surgery-alone group. It was speculated that ILN represents cell death due to the cytotoxic effects of chemotherapy and it was noted that the efficacy of BV may be related to the appearance of ILN, because BV was given to half of the cases in which ILN appeared.\textsuperscript{22} However, as for the incidence of ILN in this study, a difference was not seen between the FOLFOX or FOLFIRI group and the FOLFOX or FOLFIRI with BV group. This result suggested that ILN was not changed specifically following treatment with BV. On the other hand, the incidence of UN decreased only in the FOLFOX or FOLFIRI with BV group in this study. UN is an ongoing process that arises within areas of hypoxia as a tumor enlarges and outgrows its vascular supply.\textsuperscript{28} Our results suggested that the anti-VEGF action affects the enlargement and outgrowth of CRLM.

In this examination, it is possible that in some cases the histological findings of the chemotherapy group were similar to those of the surgery-alone group. This demonstrates the risk of performing histologic effect measurement of chemotherapy only for a single finding. A significant difference was seen in the incidence of pathological findings between the surgery-alone group and the FOLFOX or FOLFIRI group and the FOLFOX or FOLFIRI with BV group when more than three findings were seen among ILN, three-zonal changes, cholesterol clefts and foamy macrophages. This result indicated that cases with preoperative chemotherapy using a more effective regimen had more complex histological findings in CRLM. The pathological evaluation of preoperative chemotherapy should include analysis of various histological findings.

Previous studies have evaluated pathologic assessment of tumor regression to preoperative chemotherapy according to the ratio of residual tumor cells in CRLM.\textsuperscript{20,21,23} In this study, when we classified histological tumor regression as MjHR (mTRG1 and mTRG2), PHR (mTRG3), or NHR (mTRG4 and mTRG5) according to previously published guidelines,\textsuperscript{17,21,22} there was significantly more MjHR and PHR in cases with three or four histological findings than cases with two or fewer findings. MjHR was categorized as having major or complete histological response, and PHR was categorized as having partial histological tumor response. On the other hand, NHR was categorized as having no histological tumor regression or response. These results suggested that the existence of three or more of these four pathological features was correlated with the effects of preoperative chemotherapy for CRLM. Therefore, the histological influence of chemotherapy on the tumor tissue may provide useful information for the patient’s oncologist. In addition, it is expected that histological findings become an index for treatment choice in the case of recurrence after CRLM excision to determine whether the patient responded to preoperative chemotherapy and should use the same regimen.

We were able to show histological findings for every representative chemotherapy regimen for CRLM to clarify the effects of preoperative chemotherapy. The presentation of histological findings in contrast to the chemotherapy regimen is needed from a pathological perspective in the future.

**ACKNOWLEDGMENTS**

This work was presented in part at the 102nd Annual Meeting of the Japanese Society of Pathology, Sapporo, June 6–8, 2013.

We gratefully acknowledge the members of the Department of Molecular Diagnostic Pathology, Iwate Medical University Hospital for their support.

**DISCLOSURE**

The authors have no conflicts of interest to declare.

**REFERENCES**

1. Siegel R, Ma J, Zou Z et al. Cancer statistics 2014. CA Cancer J Clin 2014; 64: 9–29.
2. Stangl R, Altendorf-Hofmann A, Charney RM et al. Factors influencing the natural history of colorectal liver metastases. Lancet 1994; 343: 1405–10.
3. Leonard GD, Brenner B, Kemery NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005; 23: 2038–48.
4. Scheele J, Stang R, Altendorf-Hofmann A et al. Resection of colorectal liver metastases. World J Surg 1995; 19: 59–71.
5. Andres A, Majno PE, Morel P et al. Improved long-term outcome of surgery for advanced colorectal liver metastases: Reasons and implications for management on the basis of a severity score. Ann Surg Oncol 2008; 15: 134–43.
6. Petrelli NJ, Abbruzzese J, Mansfield P et al. Hepatic resection: The last surgical frontier for colorectal cancer. J Clin Oncol 2005; 23: 4475–7.
7. Giacchetti S, Ithzaki M, Grula G et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663–9.
8. Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for...
reseactable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 2008; 371: 1007–16.
9 Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 2004; 240: 644–57.
10 Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–16.
11 Stéphane Benoist AB, Christophe P, Catherine J et al. Complete response of colorectal liver metastases after chemotherapy: Does it mean cure? J Clin Oncol 2006; 24: 3939–45.
12 Delaunoit T, Alberts SR, Sargent DJ et al. Chemotherapy permits resection of metastatic colorectal cancer: Experience from Intergroup N9741. Ann Oncol 2005; 16: 425–9.
13 Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905–14.
14 Andre T, Bensmaine MA, Louvet C et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999; 17: 3560–68.
15 Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355: 1041–7.
16 Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42.
17 Klinger M, Tamandl D, Eipeldauer S et al. Bevacizumab improves pathological response of colorectal liver metastases treated with XELOX/FOLFOX. Ann Oncol 2010; 17: 2059–65.
18 Gruenberger B, Tamandl D, Schueler J et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26: 1830–35.
19 Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539–44.
20 Blazer DG 3rd, Kishi Y, Maru DM et al. Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 26: 5344–51.
21 Rubbia-Brandt L, Giostra E, Brezaut C et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007; 18: 299–304.
22 Chang HH, Leeper WR, Chan G et al. Infarct-like necrosis: A distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy. Am J Surg Pathol 2012; 36: 570–76.
23 Aloysius MM, Zaitoun AM, Beckingham IJ et al. The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: A comparative study. Virchows Arch 2007; 451: 943–8.
24 Mentha G, Terraz S, Morel P et al. Dangerous halo after neoadjuvant chemotherapy and two-step hepatectomy for colorectal liver metastases. Br J Surg 2009; 96: 95–103.
25 Allen PJ, Kemeny N, Jarnagin W et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003; 7: 109–15.
26 Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12: 19–23.
27 Douillard JY, Siena S, Cassidy J et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 2010; 28: 4697–705.
28 Ribba B, Watkin E, Tod M et al. A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers. Eur J Cancer 2011; 47: 479–90.